Claim: A molecule called SLAMF6 exhausts cancer-fighting T cells over time, which may explain why immunotherapy stops working for many patients.

First requested: June 19, 2026 at 10:33 AM
62%

IsItCap Score

Truth Potential Meter

Moderately Credible

AI consensusWeak

Grader consensus is weak.
Range 38%–70% (spread Δ32).
The graders diverge. Treat the combined score as uncertain and read the sources carefully.
Read analysis summary

OpenAI Grade

0%
20%
40%
60%
80%
70%

Perplexity Grade

0%
20%
40%
60%
80%
38%

Google Gemini Grade

0%
20%
40%
60%
80%
50%
Shareable summary
Verdict: Questionable
  • A 2023 study found high SLAMF6 linked to better prognosis in some cancers.
  • One study says SLAMF6 is not a classic exhaustion marker.
/r/slamf6-exhausts-cancer-fighting-t-cells

Analysis Summary

The claim that SLAMF6 exhausts cancer-fighting T cells over time is mostly true, supported by peer-reviewed studies indicating its role in T-cell dysfunction and immune exhaustion. Researchers highlight that blocking SLAMF6 can restore T-cell function and improve responses to immunotherapy. However, some studies dispute this, suggesting SLAMF6 may not be a direct cause of exhaustion but rather an inhibitory checkpoint that can enhance T-cell responses when absent. This nuance indicates a more complex relationship than initially suggested. The models diverge sharply — treat this as higher-uncertainty. OpenAI comes in highest (70%), while Perplexity is lowest (38%). While the majority of evidence supports the idea that SLAMF6 contributes to T-cell exhaustion, some opposing studies argue that SLAMF6 should not be classified solely as an exhaustion marker. These studies suggest that its absence can actually improve T-cell responses against tumors, which complicates the understanding of SLAMF6's role in immunotherapy. This divergence in findings does not negate the claim but highlights the need for further research to clarify SLAMF6's function in T-cell dynamics and immunotherapy efficacy.
Jump to source analysis

Source quality

Truth (from sources)7.00 / 10
Source reliability8.00 / 10
Source independence6.00 / 10

Claim checks

Fits established facts7.00 / 10
Logical consistency7.00 / 10
Expert consensus6.00 / 10
Related fact checks

Source Analysis

Common arguments
Supporting the claim
  • SLAMF6 is linked to exhausted CD8+ T-cell dysfunction in cancer.
  • Blocking SLAMF6 restored T-cell function in preclinical models.
  • Recent studies describe SLAMF6 as a T-cell inhibitory receptor.
Against the claim
  • A 2023 study found high SLAMF6 linked to better prognosis in some cancers.
  • One study says SLAMF6 is not a classic exhaustion marker.
  • The evidence is preclinical and does not prove it explains most immunotherapy failure.

Mainstream Sources

Publication

pubmed.ncbi.nlm.nih.gov

Title

SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer

Summary

Peer-reviewed study reporting that SLAMF6 is linked to exhausted CD8+ T-cell dysfunction in cancer and that blocking SLAMF6 can restore T-cell function and reduce tumor burden in preclinical models.

Source details

Type: Primary
Published: 2019-07-17
Low Evidence

URL

Visit Source

Publication

news-medical.net

Title

SLAMF6 discovery offers hope for non-responding cancer patients

Summary

Science news report summarizing new research that SLAMF6 weakens T cells, promotes immune exhaustion, and may help explain why some immunotherapies stop working.

Source details

Type: Aggregator
Published: 2026-02-12
Low Evidence

URL

Visit Source

Publication

nature.com

Title

Clinical and immunological relevance of SLAMF6 expression in the tumor microenvironment of melanoma and breast cancer

Summary

Peer-reviewed paper showing SLAMF6 has a more nuanced role: it is associated with progenitor-exhausted T cells, better prognosis in some contexts, and may serve as a marker or inhibitory receptor rather than a simple exhaustion driver.

Source details

Type: Primary
Published: 2023-01-01
Low Evidence

URL

Visit Source

Alternative Sources

Publication

elifesciences.org

Title

SLAMF6 deficiency augments tumor killing and skews toward an exhausted CD8+ phenotype

Summary

This study argues SLAMF6 is not itself a bona fide exhaustion marker, but a constitutive inhibitory checkpoint whose absence can improve tumor killing by CD8+ T cells.

Source details

Type: Primary
Low Evidence

URL

Visit Source

Analysis Breakdown

True/False Spectrum (7.0)Source Credibility (8.0)Bias Assessment (6.0)Contextual Integrity (7.0)Content Coherence (7.0)Expert Consensus (6.0)68%

How to read the breakdown

Weakest areas
Independence6.0/10Consensus6.0/10
  • Truth: how well sources support the core claim.
  • Source reliability: whether the sources have a strong track record.
  • Independence: whether coverage looks one-sided or recycled.
  • Context: missing details (timeframe, definitions, scope) that change meaning.
  • Tip: if graders disagree, rely more on the summary + sources than the single number.

Detailed AnalysisPremium Feature

Get an in-depth analysis of content accuracy, source credibility, potential biases, contextual factors, claim origins, and hidden perspectives.

Create a free account to unlock premium features.

Methodology